Nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief have been recalled nationwide because they may not be sterile, which could expose users to bacteria. The recalled eye drops were sold at Walmart, Target, CVS, and other stores. Recalled products have the lot number 2552A and an expiration date of 9/30/2027. If you have a recalled bottle stop using it immediately, return it for a refund, and report any negative reactions to the FDA MedWatch program.

The U.S. Food and Drug Administration (FDA) approved a new drug to treat pancreatic cancer. Taken as daily pills, the medication treats late-stage pancreatic cancer and nearly doubles how long patients survive compared to traditional chemotherapy. The drug is called Rasonque (daraxonrasib) and it causes fewer harsh side effects like hair loss and nerve damage than chemotherapy. Right now, the medication is only available for adults with advanced pancreatic cancer who have already tried chemotherapy or are unable to take chemotherapy combinations. Without insurance, the medication costs $39,800 a month.

From 2014 to 2022, CDC data show that rates of prostate cancer have increased among men in the United States. The increase is partly due to more men being screened for prostate cancer; however, some men may not be getting screened early enough. Diagnosis of more advanced prostate cancer also increased among men in all age groups. Early diagnosis can mean better treatment options and higher survival rates. The American Cancer Society suggests men at average risk be screened starting at age 50. Men are at higher risk if they have a family history of prostate cancer, have obesity, or are Black/African American. Men at higher risk should start screening at 45 or 40 if they have multiple risk factors. A PSA blood test, prostate-specific antigen, can screen for prostate cancer.